NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: LIXTE Biotechnology's Sponsorship of the Good Health Mind, Body & Soul Summit
TL;DR
LIXTE Biotechnology sponsors a health summit to align its cancer drug LB-100 with community outreach, potentially enhancing its brand and market position in oncology.
LIXTE Biotechnology is sponsoring the Good Health Summit on February 19 at Morehouse College, featuring discussions on health equity topics like cancer and mental health.
The summit advances health equity for Black men and families by connecting scientific innovation with communities impacted by health disparities.
De La Soul's song 'Good Health' inspired this summit, evolving the group from musical pioneers to wellness advocates addressing intergenerational wellness.
Found this article helpful?
Share it with your network and spread the knowledge!
LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event focused on advancing health equity for Black men and families.
The Summit is scheduled for February 19, 2026 at Morehouse College in Atlanta, Georgia.
The Summit is developed in collaboration with Blacksmith holdings and inspired by De La Soul's music and legacy. It brings together leaders in health, culture, science, and community, and is sponsored by LIXTE Biotechnology Holdings.
LIXTE stated that the Summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its oncology compound LB-100, while creating a space to connect scientific innovation with communities most impacted by health disparities.
The Summit will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies, with its lead clinical PP2A inhibitor LB-100.
LB-100 is LIXTE's first-in-class lead clinical PP2A inhibitor that has been demonstrated to be well-tolerated in cancer patients at doses associated with anti-cancer activity, with potential to significantly enhance chemotherapies and immunotherapies.
The Summit is inspired by the music, legacy, and lived experiences of De La Soul, specifically their song 'Good Health' written following the passing of founding member David Jolicoeur (Trugoy the Dove), reflecting the group's evolution from musical pioneers to wellness advocates.
To view the full press release, visit https://ibn.fm/0kkqK. For more information about LIXTE Biotechnology, visit www.lixte.com.
Proof-of-concept clinical trials for LB-100 are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Curated from NewMediaWire
